Genmab Presents Three Positive Phase 3 Trials Supporting Potential 2027 Launches
Bitget2026/10/28 17:29- Genmab reported three positive Phase 3 trials, supporting potential approvals and launches beginning in 2027.
- EPKINLY reduced the risk of progression or death by 51% versus R-CHOP in newly diagnosed diffuse large B-cell lymphoma.
- Rina-S cut progression or death risk by 71% versus chemotherapy in platinum-resistant ovarian cancer; overall survival also improved significantly.
- Petosemtamab with pembrolizumab reduced death risk by 50% versus pembrolizumab alone in first-line recurrent or metastatic PD-L1-positive head and neck cancer.
- Estimated peak sales opportunities exceed $3 billion for EPKINLY, exceed $2 billion for Rina-S, and reach multiple billions for petosemtamab.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Circle issues 500 million USDC on the Solana network

Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

